Molecular mechanisms of diabetic retinopathy: potential therapeutic targets

Maha Coucha1, Sally L Elshaer1, Wael S Eldahshan1

  • 1Department of Clinical Pharmacy, Program in Clinical and Experimental Therapeutics, University of Georgia, Georgia, USA ; Culver Vision Discovery Institute, Georgia Regents University, Georgia, USA ; Research Service, Charlie Norwood VA Medical Center, Augusta 30912, Georgia, USA.

Insights

Diabetic retinopathy (DR) causes blindness in working adults. This review explores how oxidative stress and inflammation contribute to DR, identifying potential therapeutic targets for prevention and treatment.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Molecular Biology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population.
  • Oxidative stress is linked to diabetes complications, but general antioxidant trials have been ineffective.
  • Emerging evidence highlights the critical role of oxidative stress and inflammation in DR pathogenesis.

Purpose of the Study:

  • To review current diabetic retinopathy management strategies.
  • To present experimental therapeutic interventions for DR.
  • To identify molecular targets linking oxidative stress and inflammation for DR treatment.

Main Methods:

  • Literature review of experimental studies on DR.
  • Analysis of molecular mechanisms involving oxidative stress and inflammation.
  • Evaluation of potential therapeutic targets for DR.

Main Results:

  • Oxidative stress and inflammation are key players in the development of diabetic retinopathy.
  • Specific molecular pathways linking these processes offer potential therapeutic avenues.
  • Current management strategies and experimental interventions are discussed.

Conclusions:

  • Targeting the interplay between oxidative stress and inflammation holds promise for novel DR therapies.
  • Understanding biochemical and molecular changes in diabetes is crucial for developing effective treatments.
  • Further research into these molecular links could lead to new tools to combat diabetic retinopathy.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.9K